Results for tag: "D3 Agonist"

D3 Agonists are a class of drugs used to treat diseases of the Central Nervous System (CNS). These drugs act on the D3 receptor, a G-protein coupled receptor found in the brain and other parts of the body. D3 Agonists are used to treat a variety of CNS disorders, including schizophrenia, bipolar disorder, depression, and anxiety. They are also used to treat Parkinson's disease, Alzheimer's disease, and Huntington's disease. D3 Agonists are typically administered orally, intramuscularly, or intravenously. The D3 Agonist market is a rapidly growing segment of the CNS drug market. It is driven by the increasing prevalence of CNS disorders, as well as the development of new and improved drugs. The market is highly competitive, with many companies vying for market share. Some of the major players in the D3 Agonist market include AbbVie, AstraZeneca, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more